


Targeting Pharmacotherapy to Effectively Manage Eosinophilic Esophagitis

References

1. Aceves SS, Furuta GT, Spechler SJ. Integrated approach to treatment of children and adults with eosinophilic esophagitis. *Gastrointest Endosc Clin N Am*. 2008;18(1):195-217.
2. Bredenoord, AJ, Patel K, Schoepfer AM, et al. Disease burden and unmet need in eosinophilic esophagitis. *Am J Gastroenterol*. 2022;117(8):1231-1241.
3. ClinicalTrials.gov. Testing effectiveness of losartan in patients with EoE with or without a CTD. Updated September 24, 2020. <https://www.clinicaltrials.gov/ct2/show/NCT01808196>
4. Dellon ES. Eosinophilic esophagitis: diagnostic tests and criteria. *Curr Opin Gastroenterol*. 2012;28(4):382-388. doi:10.1097/MOG.0b013e328352b5ef
5. Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. *Gastroenterology*. 2018;154(2):319-332.e313. doi:10.1053/j.gastro.2017.06.067
6. Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of eosinophilic esophagitis in the United States. *Clin Gastroenterol Hepatol*. 2014;12(4):589-596.e581. doi:10.1016/j.cgh.2013.09.008
7. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology*. 2018;155(4):1022-1033.
8. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. *N Engl J Med*. 2022;387(25):2317-2330. doi:10.1056/NEJMoa2205982
9. de Rooij WE, Dellon ES, Parker CE, et al. Pharmacotherapies for the treatment of eosinophilic esophagitis: State of the art review. *Drugs*. 2019;79(13):1419-1434. doi:10.1007/s40265-019-01173-2
10. Dupilumab. Prescribing information. Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. Accessed February 27, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s046lbl.pdf
11. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology*. 2007;133(4):1342-1363.
12. Gómez-Aldana A, Jaramillo-Santos M, Delgado A, Jaramillo C, Lúquez-Mindiola A. Eosinophilic esophagitis: Current concepts in diagnosis and treatment. *World J Gastroenterol*. 2019;25(32):4598-4613. doi:10.3748/wjg.v25.i32.4598
13. Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. *Ann Allergy Asthma Immunol*. 2020;124(5):416-423. doi:10.1016/j.anai.2020.03.020
14. Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. *Gastroenterology*. 2020;158(4): 840-851.
15. Jensen ET, Hoffman K, Shaheen NJ, Genta RM, Dellon ES. Esophageal eosinophilia is increased in rural areas with low population density: results from a national pathology database. *Am J Gastroenterol*. 2014;109(5):668-675. doi:10.1038/ajg.2014.47



Targeting Pharmacotherapy to Effectively Manage Eosinophilic Esophagitis

16. Kumar S, Choi S, Gupta SK. Eosinophilic esophagitis—A primer for otolaryngologists. *JAMA Otolaryngol Head Neck Surg.* 2019;145(4):373-380
17. Leigh LY, Spergel JM. An in-depth characterization of a large cohort of adult patients with eosinophilic esophagitis. *Ann Allergy Asthma Immunol.* 2019;122(1):65-72.
18. Liacouras C, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol.* 2011;128(1):3-20.
19. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. *United European Gastroenterol J.* 2017;5(3):335-358. doi:10.1177/2050640616689525
20. Lucendo AJ. Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. *Expert Rev Clin Immunol.* 2020;16(1):63-77. doi:10.1080/1744666x.2019.1705784
21. Muir A, Falk FW. Eosinophilic esophagitis: A review. *JAMA.* 2021;326(13):1310-1318.
22. Navarro P, Arias Á, Arias-González L, Laserna-Mendieta EJ, Ruiz-Ponce M, Lucendo AJ. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. *Aliment Pharmacol Ther.* 2019;49(9):1116-1125. doi:10.1111/apt.15231
23. Patel R, Hirano I, Gonsalves N. Eosinophilic esophagitis: Etiology and therapy. *Annu Rev Med.* 2021;72:183-197.
24. Reed CC, Dellon ES. Eosinophilic esophagitis. *Med Clin North Am.* 2019;103(1):29-42. doi:10.1016/j.mcna.2018.08.009
25. Shaheen NJ, Mukkada V, Eichinger CS, Schofield H, Todorova L, Falk GW. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. *Dis Esophagus.* 2018;31(8). doi:10.1093/dote/doy015
26. Silva FMCE, de Oliveira EE, Ambrósio MGE, et al. Disodium cromoglycate treatment reduces T_H2 immune response and immunohistopathological features in a murine model of Eosinophilic Esophagitis. *Int Immunopharmacol.* 2020;83:106422. doi:10.1016/j.intimp.2020.106422
27. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. *Am J Gastroenterol.* 2007;102(6):1301-1306.
28. Vinit C, Dieme A, Courbage S, et al. Eosinophilic esophagitis: Pathophysiology, diagnosis, and management. *Arch Pediatr.* 2019;26(3):182-190. doi:10.1016/j.arcped.2019.02.005
29. Votto M, De Filippo M, Lenti MV, et al. Diet therapy in eosinophilic esophagitis. Focus on a personalized approach. *Front Pediatr.* 2022;9:820192.